Health / Pharmaceuticals

NEREUS™ (tradipitant): A New Era in Motion Sickness Treatment

After more than four decades, a new prescription medicine has emerged to combat motion sickness. Vanda Pharmaceuticals has announced the U.S. commercial availability of NEREUS™ (tradipitant), offering a modern, targeted approach to prevent...

May 04, 2026 02:33 Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years

NEREUS™ (tradipitant): A New Era in Motion Sickness Treatment

Image via PR Newswire

TOPIC vanda pharmaceuticals

News / Partnerships

Vanda Pharmaceuticals Becomes Founding Partner of Capital One Arena

Monumental Sports & Entertainment (MSE) has announced Vanda Pharmaceuticals as a Founding Partner for Capital One Arena. This multi-year agreement includes naming rights for the Monumental Sports Network (MNMT) broadcast studio and extensiv...

Oct 09, 2025 02:33 Monumental Sports & Entertainment Taps D.C.’s Own Vanda Pharmaceuticals as Founding Partner to Help Drive the Creation of Brand-New Downtown Arena

Finance / Biotech

Vanda Pharmaceuticals to Participate in Mizuho Neuro & Ophthalmology Summit 2025

Vanda Pharmaceuticals Inc. (VNDA) is set to participate in the Mizuho Neuro & Ophthalmology Summit 2025 in New York City on May 21, 2025. This event provides an opportunity for Vanda to engage with investors and discuss advancements in neur...

May 17, 2025 03:31 Vanda Pharmaceuticals Announces Participation in the Mizuho Neuro & Ophthalmology Summit 2025